Stocky turns companies like Madrigal Pharmaceuticals, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Madrigal Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how much money the company made and spent during April-June 2026, helping investors track progress.
Reveals the company's income and expenses for January-March 2026, indicating business performance.
Employees can now receive stock awards, aligning worker and shareholder interests in company success.
Changes how board seats are divided among different classes, affecting corporate leadership structure.
Shows company earnings and spending for January-March 2026, helping investors understand quarterly performance.
Leadership structure change affects how the board operates and makes decisions for the company.
Complete financial results for all of 2025 show annual profit, losses, and business condition.
Stocky reads Madrigal Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Madrigal Pharmaceuticals, Inc.'s most recent tracked filing was a 10-Q on 30 Jul 2026: Madrigal reports second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
This page is just a preview. Open the live, interactive version for the full picture:
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.